Initial Public Offerings and Follow-On Offerings

• J.P. Morgan Securities, Leerink Partners, Piper Sandler & Co. and William Blair & Company as underwriters in the $82 million initial public offering by CAMP4 Therapeutics Corporation
• Jefferies, J.P. Morgan Securities and the other underwriters in the $130 million follow-on offering and concurrent registered direct offering by ProKidney Corp.
• TD Securities, Cantor Fitzgerald & Co., Stifel, Nicolaus & Company and RBC Capital Markets in the $150 million follow-on offering by COMPASS Pathways plc.
• J.P. Morgan Securities as underwriter in the $285 million secondary offering by Harmony Biosciences
• Stifel, Nicolaus & Company, Truist Securities and the other underwriters in connection with the approximately $107 million U.S. initial public offering of TAT Technologies, an Israeli defense and aerospace manufacturer
• Jefferies as underwriter in the $90 million follow-on offering by Esperion Therapeutics
• Leerink Partners as underwriter in the approximately $80 million follow-on offering by PepGen Inc.
• Leerink Partners and Stifel, Nicolaus & Company as underwriters in Evolus Inc.’s $50 million follow-on offering
• TD Securities and WedBush PacGrow as underwriters in the $100 million follow-on offering by Monte Rosa Therapeutics
• TD Securities, Cantor Fitzgerald & Co., Barclays and other underwriters in multiple follow-on offerings by Humacyte, Inc., aggregating over $90 million
• Jefferies, Cantor Fitzgerald & Co. and the other underwriters in connection with Rezolute, Inc.’s approximately $60 million follow-on offering
• Stifel, Nicolaus & Company as underwriter in the $30 million follow-on offering by Precigen, Inc.
• Oppenheimer & Co. and Citizens JMP Securities as underwriters in Inovio Pharmaceutical’s approximately $36 million follow-on offering
• D.A. Davidson as underwriter in the approximately $25 million secondary offering by CPI Card Group

Venture Capital Financings

• Curbwaste in various financing transactions, including its $20 million Series B financing.
• Adam has represented a number of venture capital funds in connection with their investment activities, including Deerfield Management, Infinity Ventures, Digitalis Ventures, IAG Capital Partners and Guggenheim

At-the-Market Offerings

• Jefferies as sales agent in multiple at-the-market offering programs, including Achieve Life Sciences, Palladyne AI Corp., Corvus Pharmaceuticals, Vivani Medical, Inc., HOOKIPA Pharma, Valneva SE, Offerpad Solutions Inc., P3 Health Partners and Vuzix Corporation
• TD Securities as sales agent in several at-the-market offering programs, including COMPASS Pathways plc, Repare Therapeutics and Exscientia plc
• Leerink Partners as sales agent in the at-the-market offering programs for Harmony Biosciences and Lexeo Therapeutics
• Piper Sandler & Co. and Cantor Fitzgerald & Co. as sales agents in Arvinas Inc.’s $300 million at-the-market offering program
• Oppenheimer & Co. as sales agent in several at-the-market offering programs, including Inovio Pharmaceuticals, Y-mAbs Therapeutics and Climb Bio
• Stifel, Nicolaus & Company as sales agent in PepGen Inc.’s $100 million at-the-market offering program

Debt Financings

• Varonis Systems, Inc., a leader in data security, on its offering of $400 million of convertible senior notes and related capped call transactions
• TD Securities, BofA Securities, Goldman Sachs, Mizuho Securities and U.S. Bancorp as lead managers on an SEC-registered offering by TD Bank of $2 billion aggregate principal amount of its senior notes
• J.P. Morgan Securities and the other initial purchasers in Blackstone Mortgage Trust’s $450 million offering of senior secured notes